New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
07:06 EDTAUXL, VVUS, SNYVIVUS announces avanafil clinical data presentation
VIVUS (VVUS) announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology Congress. STENDRA, or avanafil, is approved by the FDA in the U.S. for the treatment of erectile dysfunction. VIVUS has granted Auxilium Pharmaceuticals (AUXL) exclusive marketing rights to STENDRA in the U.S. and Canada. Auxilium is in the early stages of commercializing STENDRA in the U.S. SPEDRA is the trade name for avanafil in the European Union and is approved by the European Medicines Agency for the treatment of erectile dysfunction in the EU. VIVUS has granted an exclusive license to Sanofi (SNY) to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States including Russia.
News For VVUS;SNY;AUXL From The Last 14 Days
Check below for free stories on VVUS;SNY;AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:22 EDTSNYSanofi, Regeneron announce results from four Phase 3 ODYSSEY trials
Subscribe for More Information
12:50 EDTSNYEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
12:23 EDTSNYNovartis drug data to be presented this weekend
Subscribe for More Information
10:06 EDTSNYSanofi unit treatment of Fabry's disease granted orphan status
Subscribe for More Information
08:18 EDTSNYPerrigo among companies showing interest in Omega Pharma, Bloomberg says
Subscribe for More Information
August 25, 2014
12:19 EDTSNYOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTSNYSanofi and Regeneron co-host a conference call
Subscribe for More Information
10:40 EDTSNYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
07:03 EDTVVUSVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 22, 2014
12:39 EDTSNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
09:07 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTAUXLAuxilium announces positive data from Phase 2a study of CCH with cellulite
Subscribe for More Information
05:42 EDTSNYIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information
August 18, 2014
11:41 EDTAUXLCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use